The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
ADAM17 as a Therapeutic Target in Multiple Diseases
Open accessAbstract
As a metalloproteinase specialized in releasing membrane-tethered proteins, A Disintegrin and A Metalloproteinase 17 (ADAM17), also known as Tumor necrosis factor-alpha Converting Enzyme (TACE) or less commonly CD156q, has received more than its share of attention. This is mainly because major contemporary pathologies like cancer, inflammatory and vascular diseases seem to be connected to its cleavage abilities. The involvement in such a broad spectrum of diseases is due to the large variety of substrates that ADAM17 is able to cut. ADAM17 can activate growth factors or inactivate receptors by shedding their extracellular domain from the cell membrane. Similarly, it can detach cells by cleaving cell adhesion molecules. Some of these proteolytic events are part of cleavage cascades known as Regulated Intramembrane Proteolysis and lead to intracellular signaling. It is therefore clear that ADAM17 literally fulfills a key role in diverse processes and pathologies, making it a prime target for developing therapies. Here we review the role of ADAM17 in health and disease and highlight the problems to overcome for ADAM17 to mature towards a therapeutically valuable target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149
Signalling pathways of the TNF superfamily: a double-edged sword
Aggarwal, B. B. (2003) · Nature Reviews Immunology · doi:10.1038/nri1184 · Cited by 2,793
The many faces of tumor necrosis factor in stroke
Hallenbeck, J. M. (2002) · Nature Medicine · doi:10.1038/nm1202-1363 · Cited by 367
Garton, K. J., Gough, P. J., Philalay, J., Wille, P. T., Blobel, C. P., Whitehead, R. H., Dempsey, P. J., & Raines, E. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305877200 · Cited by 282
Madrigal, J. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00292-5 · Cited by 232 · cited 1×
“Western blot detected an increase in ADAM17 protein expression in the brain cortex of rats subjected to immobilization stress [135].”
BackgroundCho, R. W., Park, J. M., Wolff, S. B. E., Xu, D., Hopf, C., Kim, J.-A., Reddy, R. C., Petralia, R. S., Perin, M. S., Linden, D. J., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.010 · Cited by 125
Cited by
Romee, R., Foley, B., Lenvik, T., Wang, Y., Zhang, B., Ankarlo, D., Luo, X., Cooley, S., Verneris, M., Walcheck, B., et al. (2013) · Blood · doi:10.1182/blood-2012-04-425397 · Cited by 552
ADAM17: a molecular switch to control inflammation and tissue regeneration
Scheller, J., Chalaris, A., Garbers, C., & Rose-John, S. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.05.005 · Cited by 526
Goth, C. K., Halim, A., Khetarpal, S. A., Rader, D. J., Clausen, H., & Schjoldager, K. T.-B. G. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511175112 · Cited by 123
Muliyil, S., Levet, C., Düsterhöft, S., Dulloo, I., Cowley, S. A., & Freeman, M. (2020) · The EMBO Journal · doi:10.15252/embj.2020104415 · Cited by 36
Role of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence.
Morancho, B., Martínez-Barriocanal, Á., Villanueva, J., & Arribas, J. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0619-7 · Cited by 13
Self-citation
Metadata
- Authors
- Arribas, J., & Esselens, C.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-07-01
- Volume
- 15
- Issue
- 20
- Pages
- 2319-2335
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2079558077
- Cited by
- 171
- References
- 6
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ADAM17 as a Therapeutic Target in Multiple Diseases. https://app.cochat.ai/papers/10.2174/138161209788682398
- The paper
- Arribas, J., & Esselens, C. (2009). ADAM17 as a Therapeutic Target in Multiple Diseases. Current Pharmaceutical Design. https://doi.org/10.2174/138161209788682398
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
